Jubilant ingrevia- Plan to enter in Fluorinated derivatives, post completion of capex aspiring to achieve annual revenue of 9500+ cr.
Significant reduction in debt, improvement of ROE and ROCE and Asset turnover
Expected q4 margin compression
Jubilant Ingrevia -as expected margin compression
capex with Estimated peak revenue of 4500 cr from 2000 cr investment
Loading suggestions...